Orbimed Advisors
New York, NYfiles as ORBIMED ADVISORS LLC
$5.3bn in 117 US stocks at the end of 30 June 2026. The top 10 are 43.1% of the money. It changed about 21.6% of the portfolio this quarter.
Value
$5.3bn
Stocks
117
Top 10 share
43.1%
Turnover
21.6%
What changed this quarter
New
Bought for the first time this quarter.
- UnitedHealth GroupUNH1.3% of the fund
- Ascendis Pharma A/SASND1.2% of the fund
- HumanaHUM1.2% of the fund
- Odyssey TherapeuticsODTX1.1% of the fund
- Arcutis BiotherapeuticsARQT1.0% of the fund
- West Pharmaceutical ServicesWST0.5% of the fund
- Aura BiosciencesAURA0.4% of the fund
- Spyre TherapeuticsSYRE0.3% of the fund
- WatersWAT0.3% of the fund
- Monopar TherapeuticsMNPR0.3% of the fund
- Travere TherapeuticsTVTX0.3% of the fund
- Taysha Gene TherapiesTSHA0.3% of the fund
- Dianthus TherapeuticsDNTH0.2% of the fund
- Spruce BiosciencesSPRB0.2% of the fund
- ErascaERAS0.2% of the fund
- Protara TherapeuticsTARA0.2% of the fund
- Zentalis PharmaceuticalsZNTL0.1% of the fund
- Xilio TherapeuticsXLO0.1% of the fund
- Neumora TherapeuticsNMRA<0.1% of the fund
- Acadia PharmaceuticalsACAD<0.1% of the fund
- Amylyx PharmaceuticalsAMLX<0.1% of the fund
- Tyra BiosciencesTYRA<0.1% of the fund
- Rapport TherapeuticsRAPP<0.1% of the fund
- AgomAb Therapeutics NVAGMB<0.1% of the fund
- Tarsus PharmaceuticalsTARS<0.1% of the fund
Added
Bought more of a stock they already held.
- Eli LillyLLY5.9% of the fund+9%
- AstrazenecaAZN3.2% of the fund+37%
- Structure TherapeuticsGPCR2.3% of the fund+50%
- Guardant HealthGH1.7% of the fund+34%
- Praxis Precision MedicinesPRAX1.5% of the fund+33%
- Prelude TherapeuticsPRLD1.4% of the fund+26%
- Abivax SAABVX1.4% of the fund+17%
- Dyne TherapeuticsDYN1.4% of the fund+11%
- CG OncologyCGON1.3% of the fund+3%
- Cogent BiosciencesCOGT1.2% of the fund+422%
- Mineralys TherapeuticsMLYS1.1% of the fund+3%
- Q32 BioQTTB1.0% of the fund+83%
- Thermo Fisher ScientificTMO0.9% of the fund+95%
- Palvella TherapeuticsPVLA0.8% of the fund+117%
- Rhythm PharmaceuticalsRYTM0.7% of the fund+3%
- Syndax PharmaceuticalsSNDX0.6% of the fund+60%
- Forte Biosciences0.6% of the fund+32%
- Nektar TherapeuticsNKTR0.6% of the fund+69%
- Krystal BiotechKRYS0.6% of the fund+20%
- Kiniksa Pharmaceuticals InternationalKNSA0.5% of the fund+133%
- SavaraSVRA0.5% of the fund+524%
- Biocryst PharmaceuticalsBCRX0.4% of the fund+30%
- BioAge LabsBIOA0.4% of the fund+6%
- Lexeo TherapeuticsLXEO0.3% of the fund+10%
- Revolution MedicinesRVMD0.3% of the fund+36%
Cut
Sold some of their stake.
- Enliven TherapeuticsELVN6.5% of the fund-15%
- MBX BiosciencesMBX3.6% of the fund-6%
- Sionna TherapeuticsSION2.1% of the fund-28%
- Argenx SEARGX1.6% of the fund-32%
- uniQureQURE1.6% of the fund-15%
- Edwards LifesciencesEW1.4% of the fund-32%
- Boston ScientificBSX1.2% of the fund-38%
- Intuitive SurgicalISRG1.2% of the fund-24%
- Xenon PharmaceuticalsXENE1.0% of the fund-16%
- StrykerSYK1.0% of the fund-13%
- 00.6% of the fund-9%
- Axsome TherapeuticsAXSM0.5% of the fund-45%
- Trevi TherapeuticsTRVI0.5% of the fund-42%
- Disc MedicineIRON0.5% of the fund-67%
- Relmada TherapeuticsRLMD0.5% of the fund-23%
- UroGen PharmaURGN0.5% of the fund-23%
- Sutro BiopharmaSTRO0.5% of the fund-7%
- NeuroPaceNPCE0.5% of the fund-28%
- Oric PharmaceuticalsORIC0.4% of the fund-25%
- Helus PharmaHELP0.4% of the fund-15%
- Whitehawk TherapeuticsWHWK0.3% of the fund-6%
- Definium TherapeuticsDFTX0.3% of the fund-55%
- Janux TherapeuticsJANX0.2% of the fund-47%
- Adicet BioACET0.1% of the fund-18%
- Bicara TherapeuticsBCAX0.1% of the fund-71%
Sold out
Sold their entire stake.
- PfizerPFE-100%
- DanaherDHR-100%
- Ascendis Pharma A/SASND-100%
- Esperion Therapeutics INC NE-100%
- BrightSpring Health ServicesBTSG-100%
- AmgenAMGN-100%
- Alignment HealthcareALHC-100%
- Regeneron PharmaceuticalsREGN-100%
- CarlsmedCARL-100%
- Gilead SciencesGILD-100%
- Heron TherapeuticsHRTX-100%
- Avalo TherapeuticsAVTX-100%
- COMPASS PathwaysCMPS-100%
- ADC Therapeutics SAADCT-100%
- Cullinan TherapeuticsCGEM-100%
- Jade BiosciencesJBIO-100%
- C4 TherapeuticsCCCC-100%
- AVITA MedicalRCEL-100%
- Kalvista Pharmaceuticals-100%
- Vistagen TherapeuticsVTGN-100%
Holdings
- Structure TherapeuticsGPCR
- Share
- 2.3%
- Value
- $119m
- Shares
- 2,209,400
+50%
- Argenx SEARGX
- Share
- 1.6%
- Value
- $86m
- Shares
- 92,880
-32%
- Abivax SAABVX
- Share
- 1.4%
- Value
- $73m
- Shares
- 546,522
+17%
- Odyssey TherapeuticsODTX
- Share
- 1.1%
- Value
- $56m
- Shares
- 3,001,198
New
- Crinetics PharmaceuticalsCRNX
- Share
- 0.7%
- Value
- $37m
- Shares
- 999,000
Held
- Forte Biosciences
- Share
- 0.6%
- Value
- $34m
- Shares
- 1,577,705
+32%
- 0
- Share
- 0.6%
- Value
- $30m
- Shares
- 5,680,186
-9%
- Helus PharmaHELP
- Share
- 0.4%
- Value
- $22m
- Shares
- 3,271,400
-15%
- Bright Minds BiosciencesDRUG
- Share
- 0.1%
- Value
- $7m
- Shares
- 93,000
+133%
- AtaiBeckleyATAI
- Share
- <0.1%
- Value
- $4m
- Shares
- 797,500
+130%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Edgewise TherapeuticsEWTX | 12.0% | $631m | 15,518,492 | Held |
| Enliven TherapeuticsELVN | 6.5% | $344m | 6,776,632 | -15% |
| Eli LillyLLY | 5.9% | $309m | 257,900 | +9% |
| MBX BiosciencesMBX | 3.6% | $189m | 3,428,736 | -6% |
| Sinovac BiotechSVA | 3.5% | $184m | 2,718,735 | Held |
| AstrazenecaAZN | 3.2% | $171m | 915,700 | +37% |
| Structure TherapeuticsGPCR | 2.3% | $119m | 2,209,400 | +50% |
| Sionna TherapeuticsSION | 2.1% | $112m | 2,555,877 | -28% |
| Corvus PharmaceuticalsCRVS | 2.0% | $107m | 7,165,006 | Held |
| ArriVent BioPharmaAVBP | 2.0% | $105m | 3,027,328 | Held |
| Guardant HealthGH | 1.7% | $88m | 583,700 | +34% |
| Argenx SEARGX | 1.6% | $86m | 92,880 | -32% |
| MerckMRK | 1.6% | $85m | 663,400 | Held |
| uniQureQURE | 1.6% | $83m | 1,807,486 | -15% |
| Praxis Precision MedicinesPRAX | 1.5% | $77m | 230,100 | +33% |
| Edwards LifesciencesEW | 1.4% | $76m | 834,900 | -32% |
| Prelude TherapeuticsPRLD | 1.4% | $73m | 13,724,571 | +26% |
| Abivax SAABVX | 1.4% | $73m | 546,522 | +17% |
| Dyne TherapeuticsDYN | 1.4% | $72m | 3,235,684 | +11% |
| NateraNTRA | 1.4% | $71m | 262,000 | Held |
| CG OncologyCGON | 1.3% | $69m | 972,800 | +3% |
| UnitedHealth GroupUNH | 1.3% | $67m | 161,100 | New |
| ARS PharmaceuticalsSPRY | 1.3% | $66m | 8,288,510 | Held |
| Ascendis Pharma A/SASND | 1.2% | $65m | 244,456 | New |
| HumanaHUM | 1.2% | $65m | 164,100 | New |
| Cogent BiosciencesCOGT | 1.2% | $65m | 1,681,300 | +422% |
| Boston ScientificBSX | 1.2% | $63m | 1,483,200 | -38% |
| Intuitive SurgicalISRG | 1.2% | $63m | 157,900 | -24% |
| Mineralys TherapeuticsMLYS | 1.1% | $57m | 2,110,300 | +3% |
| Odyssey TherapeuticsODTX | 1.1% | $56m | 3,001,198 | New |
| Xenon PharmaceuticalsXENE | 1.0% | $54m | 892,471 | -16% |
| Arcutis BiotherapeuticsARQT | 1.0% | $54m | 2,042,000 | New |
| Bristol-Myers SquibbBMY | 1.0% | $53m | 925,000 | Held |
| Q32 BioQTTB | 1.0% | $53m | 4,127,987 | +83% |
| StrykerSYK | 1.0% | $50m | 159,100 | -13% |
| Caris Life SciencesCAI | 0.9% | $50m | 2,806,811 | Held |
| Thermo Fisher ScientificTMO | 0.9% | $45m | 90,700 | +95% |
| Palvella TherapeuticsPVLA | 0.8% | $45m | 292,360 | +117% |
| Elevance HealthELV | 0.8% | $44m | 114,700 | Held |
| Shattuck LabsSTTK | 0.8% | $44m | 6,306,127 | Held |
| Upstream BioUPB | 0.7% | $39m | 5,693,589 | Held |
| Crinetics PharmaceuticalsCRNX | 0.7% | $37m | 999,000 | Held |
| Rhythm PharmaceuticalsRYTM | 0.7% | $36m | 322,900 | +3% |
| Syndax PharmaceuticalsSNDX | 0.6% | $34m | 1,542,000 | +60% |
| Forte Biosciences | 0.6% | $34m | 1,577,705 | +32% |
| Compass TherapeuticsCMPX | 0.6% | $33m | 15,219,994 | Held |
| Nektar TherapeuticsNKTR | 0.6% | $32m | 465,346 | +69% |
| Krystal BiotechKRYS | 0.6% | $31m | 83,200 | +20% |
| 0 | 0.6% | $30m | 5,680,186 | -9% |
| Axsome TherapeuticsAXSM | 0.5% | $29m | 117,578 | -45% |
| Kiniksa Pharmaceuticals InternationalKNSA | 0.5% | $27m | 420,600 | +133% |
| Trevi TherapeuticsTRVI | 0.5% | $27m | 1,430,293 | -42% |
| Disc MedicineIRON | 0.5% | $26m | 357,535 | -67% |
| West Pharmaceutical ServicesWST | 0.5% | $25m | 70,600 | New |
| Relmada TherapeuticsRLMD | 0.5% | $25m | 3,631,195 | -23% |
| UroGen PharmaURGN | 0.5% | $25m | 676,187 | -23% |
| Sutro BiopharmaSTRO | 0.5% | $25m | 743,944 | -7% |
| SavaraSVRA | 0.5% | $24m | 3,959,900 | +524% |
| NeuroPaceNPCE | 0.5% | $24m | 1,505,125 | -28% |
| Aura BiosciencesAURA | 0.4% | $24m | 3,333,333 | New |
| Oric PharmaceuticalsORIC | 0.4% | $22m | 2,015,000 | -25% |
| Helus PharmaHELP | 0.4% | $22m | 3,271,400 | -15% |
| Biocryst PharmaceuticalsBCRX | 0.4% | $19m | 1,852,000 | +30% |
| BioAge LabsBIOA | 0.4% | $18m | 752,153 | +6% |
| Lexeo TherapeuticsLXEO | 0.3% | $18m | 3,947,850 | +10% |
| Whitehawk TherapeuticsWHWK | 0.3% | $18m | 3,934,296 | -6% |
| Definium TherapeuticsDFTX | 0.3% | $17m | 365,400 | -55% |
| Spyre TherapeuticsSYRE | 0.3% | $17m | 186,145 | New |
| Corbus Pharmaceuticals HoldingsCRBP | 0.3% | $16m | 1,737,287 | Held |
| Vera TherapeuticsVERA | 0.3% | $16m | 369,596 | Held |
| AlumisALMS | 0.3% | $15m | 548,163 | Held |
| EyePointEYPT | 0.3% | $15m | 1,069,147 | Held |
| WatersWAT | 0.3% | $15m | 40,300 | New |
| Monopar TherapeuticsMNPR | 0.3% | $15m | 157,423 | New |
| Travere TherapeuticsTVTX | 0.3% | $14m | 253,000 | New |
| Taysha Gene TherapiesTSHA | 0.3% | $14m | 2,000,000 | New |
| BiogenBIIB | 0.3% | $13m | 61,600 | Held |
| Revolution MedicinesRVMD | 0.3% | $13m | 70,500 | +36% |
| Dianthus TherapeuticsDNTH | 0.2% | $11m | 115,000 | New |
| Spruce BiosciencesSPRB | 0.2% | $11m | 200,000 | New |
| LifeStance Health GroupLFST | 0.2% | $10m | 947,400 | +89% |
| ErascaERAS | 0.2% | $9m | 495,900 | New |
| Protara TherapeuticsTARA | 0.2% | $8m | 2,220,000 | New |
| Keros TherapeuticsKROS | 0.2% | $8m | 759,155 | Held |
| Janux TherapeuticsJANX | 0.2% | $8m | 524,700 | -47% |
| Tectonic TherapeuticTECX | 0.1% | $8m | 226,600 | Held |
| Adicet BioACET | 0.1% | $7m | 844,787 | -18% |
| PharvarisPHVS | 0.1% | $7m | 205,400 | Held |
| Alto NeuroscienceANRO | 0.1% | $7m | 257,852 | +54% |
| Zentalis PharmaceuticalsZNTL | 0.1% | $7m | 1,390,576 | New |
| Bright Minds BiosciencesDRUG | 0.1% | $7m | 93,000 | +133% |
| ALX Oncology HoldingsALXO | 0.1% | $6m | 2,866,256 | Held |
| Xilio TherapeuticsXLO | 0.1% | $6m | 592,300 | New |
| Bicara TherapeuticsBCAX | 0.1% | $6m | 191,100 | -71% |
| ImageneBioIMA | 0.1% | $5m | 909,269 | +140% |
| Protagonist TherapeuticsPTGX | <0.1% | $5m | 42,100 | Held |
| Alnylam PharmaceuticalsALNY | <0.1% | $5m | 17,000 | -86% |
| Palisade BIOPALI | <0.1% | $5m | 2,333,000 | Held |
| AtaiBeckleyATAI | <0.1% | $4m | 797,500 | +130% |
| PTC TherapeuticsPTCT | <0.1% | $4m | 49,100 | Held |
Showing the largest 100 of 117.
Options (8)
- Spdr Series TrustXBI
- Type
- Put
- Value
- $47m
- Contracts
- 300,000
- Abivax SAABVX
- Type
- Call
- Value
- $27m
- Contracts
- 200,000
- Protagonist TherapeuticsPTGX
- Type
- Call
- Value
- $18m
- Contracts
- 150,000
- Revolution MedicinesRVMD
- Type
- Call
- Value
- $9m
- Contracts
- 50,000
- Palvella TherapeuticsPVLA
- Type
- Call
- Value
- $6m
- Contracts
- 40,000
- UnitedHealth GroupUNH
- Type
- Call
- Value
- $4m
- Contracts
- 10,000
- Elevance HealthELV
- Type
- Call
- Value
- $4m
- Contracts
- 10,000
- SELLAS Life Sciences GroupSLS
- Type
- Put
- Value
- $1m
- Contracts
- 92,500
| Company | Type | Value | Contracts |
|---|---|---|---|
| Spdr Series TrustXBI | Put | $47m | 300,000 |
| Abivax SAABVX | Call | $27m | 200,000 |
| Protagonist TherapeuticsPTGX | Call | $18m | 150,000 |
| Revolution MedicinesRVMD | Call | $9m | 50,000 |
| Palvella TherapeuticsPVLA | Call | $6m | 40,000 |
| UnitedHealth GroupUNH | Call | $4m | 10,000 |
| Elevance HealthELV | Call | $4m | 10,000 |
| SELLAS Life Sciences GroupSLS | Put | $1m | 92,500 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 32.4% since 30 June 2025.
Where the money is
Health care93.5%
Other6.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.